Koyfin Home > Directory > Health Care > Acceleron Pharma > EBITDA

Acceleron Pharma EBITDA Chart (XLRN)

Acceleron Pharma annual/quarterly EBITDA from 2012 to 2020. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Acceleron Pharma EBITDA for the quarter ending June 06, 2020 was $-18m a -166.72% increase of 30m year over year
  • Acceleron Pharma EBITDA for the last 12 months ending June 06, 2020 was $-141m a -1.99% increase of 3m year over year
  • Acceleron Pharma Annual EBITDA for 2019 was $-133m a 8.93% decrease of -12m from 2018
  • Acceleron Pharma Annual EBITDA for 2018 was $-121m a 11.20% decrease of -14m from 2017
  • Acceleron Pharma Annual EBITDA for 2017 was $-107m a 39.87% decrease of -43m from 2016
Other Income Statement Metrics:
  • Acceleron Pharma Net Income for the quarter ending December 12, 2018 was $-35m a 24.52% decrease of -9m year over year
  • Acceleron Pharma Total Revenue for the quarter ending September 09, 2018 was $3m a -13.72% decrease of 0m year over year
View Chart On Koyfin

Quarterly XLRN EBITDA Data

06/2020$-18m
03/2020$-51m
12/2019$-25m
09/2019$-48m
06/2019$-20m
03/2019$-40m
12/2018$-36m
09/2018$-29m
06/2018$-29m
03/2018$-27m

Annual XLRN EBITDA Data

2019$-133m
2018$-121m
2017$-107m
2016$-64m
2015$-60m
2014$-49m
2013$8m
2012$-28m
2011$42m